MX2011012013A - Peptidos ttk y vacunas que incluyen los mismos. - Google Patents
Peptidos ttk y vacunas que incluyen los mismos.Info
- Publication number
- MX2011012013A MX2011012013A MX2011012013A MX2011012013A MX2011012013A MX 2011012013 A MX2011012013 A MX 2011012013A MX 2011012013 A MX2011012013 A MX 2011012013A MX 2011012013 A MX2011012013 A MX 2011012013A MX 2011012013 A MX2011012013 A MX 2011012013A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- ttk
- methods
- antigen
- inducing
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 101150057353 Ttk gene Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describen vacunas de péptido contra cáncer. En particular, se proporcionan péptidos de epitopo derivados del gen TTK que producen CTLs. También se proporcionan células que presentan antígenos y CTLs aislados que se dirigen a tales péptidos, así como métodos para inducir la célula que presenta antígeno, o CTL. La presente invención proporciona además composiciones farmacéuticas que contienen como péptidos de ingredientes activos derivados de TTK o polinucleótidos que codifican los péptidos. Adicionalmente, la presente invención proporciona métodos para el tratamiento y/o profilaxis (es decir, prevención) de cánceres (tumores), y/o la prevención de recurrencía postoperativa de los mismos, así como métodos para inducir CTLs, métodos para inducir inmunidad anti-tumor, usando los péptidos derivados de TTK, polinucleótidos que codifican los péptidos, o células que presentan antígeno que presentan los péptidos, o las composiciones farmacéuticas de la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21601709P | 2009-05-11 | 2009-05-11 | |
PCT/JP2010/003166 WO2010131452A1 (en) | 2009-05-11 | 2010-05-10 | Ttk peptides and vaccines including the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011012013A true MX2011012013A (es) | 2012-02-23 |
Family
ID=43084837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011012013A MX2011012013A (es) | 2009-05-11 | 2010-05-10 | Peptidos ttk y vacunas que incluyen los mismos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US8530430B2 (es) |
EP (1) | EP2430039A4 (es) |
JP (1) | JP5786178B2 (es) |
KR (1) | KR20120029394A (es) |
CN (1) | CN102459314B (es) |
AU (1) | AU2010248702A1 (es) |
BR (1) | BRPI1013938A2 (es) |
CA (1) | CA2761393A1 (es) |
MX (1) | MX2011012013A (es) |
RU (1) | RU2531348C2 (es) |
SG (1) | SG175998A1 (es) |
TW (1) | TW201102081A (es) |
WO (1) | WO2010131452A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201701866QA (en) | 2012-09-11 | 2017-04-27 | Oncotherapy Science Inc | Ube2t peptides and vaccines containing the same |
WO2018090257A1 (zh) * | 2016-11-16 | 2018-05-24 | 深圳华大基因研究院 | 多肽及其应用 |
WO2018098636A1 (zh) * | 2016-11-29 | 2018-06-07 | 深圳华大基因研究院 | 多肽及其应用 |
FI3652606T3 (fi) * | 2017-07-12 | 2023-03-16 | Nouscom Ag | Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon |
WO2024077601A1 (en) * | 2022-10-14 | 2024-04-18 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Peptide vaccines against glioma and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187548B1 (en) * | 1993-05-23 | 2001-02-13 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Methods using human calcium sensor protein, fragments thereof and DNA encoding same |
US20030045491A1 (en) | 2001-02-23 | 2003-03-06 | Christoph Reinhard | TTK in diagnosis and as a therapeutic target in cancer |
KR100876327B1 (ko) | 2001-02-21 | 2008-12-31 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 진단에서의, 그리고 암에서 치료 표적으로서의 ttk |
US7501242B2 (en) * | 2001-02-21 | 2009-03-10 | Novartis Vaccines And Diagnostics, Inc. | Detection of colon or breast cancer by measuring TTK polynucleotide expression |
AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
EP1485871A2 (en) * | 2002-02-27 | 2004-12-15 | Michael Rik Frans Brands | A data integration and knowledge management solution |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
PT1581812E (pt) | 2003-01-06 | 2008-09-22 | Wyeth Corp | Composições e métodos para diagnóstico e tratamento de cancros do cólon |
WO2004070062A2 (en) | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
EP1670955A2 (en) | 2003-09-22 | 2006-06-21 | Rosetta Inpharmatics LLC. | Synthetic lethal screen using rna interference |
JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
GB0426393D0 (en) | 2004-12-01 | 2005-01-05 | Cancer Rec Tech Ltd | Materials and methods relating to modulators of spindle checkpoint kinases |
KR101357040B1 (ko) | 2004-12-08 | 2014-02-03 | 아벤티스 파마슈티칼스 인크. | 도세탁셀에 대한 내성 또는 감수성을 측정하는 방법 |
EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
EP2325305B1 (en) | 2005-02-25 | 2014-02-12 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides |
JP2009502115A (ja) | 2005-07-27 | 2009-01-29 | オンコセラピー・サイエンス株式会社 | 小細胞肺癌の診断方法 |
JP5150909B2 (ja) | 2005-07-27 | 2013-02-27 | オンコセラピー・サイエンス株式会社 | 食道癌を診断する方法 |
WO2008072777A2 (en) | 2006-12-13 | 2008-06-19 | Oncotherapy Science, Inc. | Ttk as tumor marker and therapeutic target for lung cancer |
TWI610939B (zh) * | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
US8492356B2 (en) | 2007-12-21 | 2013-07-23 | University Health Network | Methods of inhibiting tumor growth using TTK antagonists |
TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2010
- 2010-05-05 TW TW099114328A patent/TW201102081A/zh unknown
- 2010-05-10 RU RU2011150283/04A patent/RU2531348C2/ru not_active IP Right Cessation
- 2010-05-10 US US13/320,022 patent/US8530430B2/en not_active Expired - Fee Related
- 2010-05-10 CA CA2761393A patent/CA2761393A1/en not_active Abandoned
- 2010-05-10 EP EP10774711A patent/EP2430039A4/en not_active Withdrawn
- 2010-05-10 WO PCT/JP2010/003166 patent/WO2010131452A1/en active Application Filing
- 2010-05-10 JP JP2011548451A patent/JP5786178B2/ja not_active Expired - Fee Related
- 2010-05-10 AU AU2010248702A patent/AU2010248702A1/en not_active Abandoned
- 2010-05-10 MX MX2011012013A patent/MX2011012013A/es active IP Right Grant
- 2010-05-10 CN CN201080031259.2A patent/CN102459314B/zh not_active Expired - Fee Related
- 2010-05-10 BR BRPI1013938A patent/BRPI1013938A2/pt not_active IP Right Cessation
- 2010-05-10 KR KR1020117027534A patent/KR20120029394A/ko not_active Application Discontinuation
- 2010-05-10 SG SG2011082963A patent/SG175998A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2012526519A (ja) | 2012-11-01 |
EP2430039A1 (en) | 2012-03-21 |
CN102459314A (zh) | 2012-05-16 |
RU2011150283A (ru) | 2013-06-20 |
EP2430039A4 (en) | 2012-12-05 |
WO2010131452A1 (en) | 2010-11-18 |
RU2531348C2 (ru) | 2014-10-20 |
KR20120029394A (ko) | 2012-03-26 |
AU2010248702A1 (en) | 2011-11-17 |
BRPI1013938A2 (pt) | 2019-09-24 |
CA2761393A1 (en) | 2010-11-18 |
CN102459314B (zh) | 2016-01-20 |
US20120135020A1 (en) | 2012-05-31 |
US8530430B2 (en) | 2013-09-10 |
SG175998A1 (en) | 2011-12-29 |
JP5786178B2 (ja) | 2015-09-30 |
TW201102081A (en) | 2011-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010014044A (es) | Peptidos de epitope cdca1 y vacunas que contienen los mismos. | |
MX2015012012A (es) | Peptidos de kntc2 y vacunas que los contienen. | |
GB201004575D0 (en) | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers | |
PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
MX2011012013A (es) | Peptidos ttk y vacunas que incluyen los mismos. | |
MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. | |
MX2011010191A (es) | Peptidos c6orf167 y vacunas que continen los mismos. | |
MX2022006022A (es) | Peptido derivado de depdc1 y vacuna que lo contiene. | |
EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
SG10201900933YA (en) | Koc1-derived peptide and vaccine including same | |
MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
BR112013005448A2 (pt) | peptídeos de ttll4 e vacinas contendo os mesmos. | |
MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. | |
EP4282883A3 (en) | Cdca1-derived peptide and vaccine containing same | |
MX2021001357A (es) | Peptido derivado de cdca1 y vacuna que lo contiene. | |
MX2012006770A (es) | Peptidos tmem22 y vacunas que incluyen los mismos. | |
SG10201900835XA (en) | Urlc10-derived peptide and vaccine containing same | |
MX2012006376A (es) | Peptidos mybl2 y vacunas que los contienen. | |
MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC | |
MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
EA202090821A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |